Javad Ghaffari - Antimicrobial Resistant Nosocomial Infection Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
Soheila Shahmohammadi - Antimicrobial Resistant Nosocomial Infection Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran
Hossein Ashrafi - Beatson Institute for Cancer Research, Faculty of Medicine, University of Glasgow, Glasgow, UK
Ali Reza Ranjbar - Research Institute of Interventional Allergology and Immunology, Bonn, Germany
Negar Ghaffari - Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran

Generally, ۱۵-۲۵% of general population experience urticaria during their life. The prevalence of chronic urticaria is about ۰.۱-۰.۳% in children and most often occurs between ages of ۶-۱۱ years. There are several causes for development of chronic urticaria. Known etiologies of chronic urticaria in children vary from ۲۱% to ۸۳%. Chronic urticaria caused by infections is more common in children than adults. Diagnosis of chronic urticaria is based on clinical history and physical examination and routine laboratory testing in the absence of a clinical history is rarely helpful. Similar to adults, antihistamines are the first line of treatment. Omalizumab as a biological engineering molecule is a recombinant humanized monoclonal antibody, which targets the CH۳ domain of the ε chain of the free IgE. Omalizumab has been used in patients with H۱-antihistamine-refractory chronic idiopathic urticaria (CIU). Here in we made a review about possible mechanisms by which omalizumab may be effective in children above ۱۲ years with chronic urticaria, and also focused on its therapeutic effects, onset criteria and possible side effects.

Omalizumab, Chronic Urticaria, Child, Therapeutics